Edition:
United Kingdom

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

160.22USD
18 Jan 2019
Change (% chg)

$3.66 (+2.34%)
Prev Close
$156.56
Open
$157.77
Day's High
$160.36
Day's Low
$156.38
Volume
865,768
Avg. Vol
643,050
52-wk High
$197.00
52-wk Low
$125.84

Select another date:

Fri, Jan 11 2019

Photo

Health Canada places restrictions on Allergan's fibroid treatment Esmya

Canada's health regulator on Friday said it was restricting the use of Allergan Plc's uterine fibroid treatment Esmya after discovering a risk of serious liver injury from the drug.

Health Canada places restrictions on Allergan's fibroid treatment Esmya

Jan 11 Canada's health regulator on Friday said it was restricting the use of Allergan Plc's uterine fibroid treatment Esmya after discovering a risk of serious liver injury from the drug.

Allergan stops sale of textured breast implants in Europe, shares sink

NEW YORK Drugmaker Allergan Plc said on Wednesday it would take its textured breast implants off the market in Europe, a day after a French regulatory body ordered a recall of the implants, which have been linked to a rare form of cancer.

Allergan stops sale of textured breast implants in Europe, shares sink

NEW YORK Drugmaker Allergan Plc said on Wednesday it would take its textured breast implants off the market in Europe, a day after a French regulatory body ordered a recall of the implants, which have been linked to a rare form of cancer.

UPDATE 2-Allergan stops sale of textured breast implants in Europe, shares sink

NEW YORK, Dec 19 Drugmaker Allergan Plc said on Wednesday it would take its textured breast implants off the market in Europe, a day after a French regulatory body ordered a recall of the implants, which have been linked to a rare form of cancer.

CORRECTED-UPDATE 1-Allergan stops sales of textured breast implants in Europe

PARIS, Dec 19 Drugmaker Allergan said on Wednesday it would take its textured breast implants off the market in Europe, a day after a French regulatory body ordered the recall of the implants, which have been linked to a rare form of cancer.

Allergan stops sales in Europe of breast implants linked to cancer

PARIS, Dec 19 Breast implants made by drugmaker Allergan, which have been linked to a rare form of cancer, are being taken off the market in Europe, said a French regulatory body.

Revance Therapeutics' Botox rival succeeds in late-stage trial

A potential rival for Allergan Plc's blockbuster Botox has passed a late-stage study, putting drug developer Revance Therapeutics Inc on course to file for U.S. marketing approval next year.

UPDATE 2-Revance Therapeutics' Botox rival succeeds in late-stage trial

Dec 4 A potential rival for Allergan Plc's blockbuster Botox has passed a late-stage study, putting drug developer Revance Therapeutics Inc on course to file for U.S. marketing approval next year.

Allergan says offers undervalue business units for sale, shares fall

Allergan Plc on Tuesday expressed disappointment in early offers from potential buyers for business units it has been trying to sell, and its shares fell more than 6 percent.

Select another date: